Thalidomide

Generic Name
Thalidomide
Brand Names
Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
Drug Type
Small Molecule
Chemical Formula
C13H10N2O4
CAS Number
50-35-1
Unique Ingredient Identifier
4Z8R6ORS6L
Background

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...

Indication

Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

Associated Conditions
Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
Associated Therapies
-
Clinical Trials
Related News

Thalidomide for Multiple Myeloma

Phase 3
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Thalidomide
First Posted Date
2002-05-30
Last Posted Date
2018-10-31
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
27
Registration Number
NCT00038233
Locations
🇺🇸

University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
First Posted Date
2002-05-30
Last Posted Date
2018-11-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
18
Registration Number
NCT00038181
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Thalidomide-Dexamethasone for Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Thalidomide
Drug: Dexamethasone
First Posted Date
2002-05-29
Last Posted Date
2018-10-31
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
83
Registration Number
NCT00038090
Locations
🇺🇸

University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Blood and Marrow Transplant Clinical Research Network

First Posted Date
2001-09-07
Last Posted Date
2016-02-18
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00023530
Locations
🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

University of California at San Diego, La Jolla, California, United States

🇺🇸

Stanford University, Palo Alto, California, United States

and more 13 locations

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

Phase 2
Completed
Conditions
HIV Infections
HIV Wasting Syndrome
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Celgene Corporation
Target Recruit Count
75
Registration Number
NCT00002127
Locations
🇺🇸

Marin County Specialty Clinic, Greenbrae, California, United States

🇺🇸

Gottlieb Med Group, Sherman Oaks, California, United States

🇺🇸

George Washington Univ Med Ctr, Washington, District of Columbia, United States

and more 10 locations

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Rockefeller University
Target Recruit Count
12
Registration Number
NCT00002392
Locations
🇺🇸

Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States

Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Louisiana State University Health Sciences Center in New Orleans
Target Recruit Count
20
Registration Number
NCT00002174
Locations
🇺🇸

Ochsner Clinic, New Orleans, Louisiana, United States

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

Not Applicable
Completed
Conditions
HIV Infections
HIV Wasting Syndrome
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Celgene Corporation
Registration Number
NCT00002157
Locations
🇺🇸

Celgene Corp, Warren, New Jersey, United States

Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV

First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Aaron Diamond AIDS Research Center
Registration Number
NCT00002104
Locations
🇺🇸

Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States

🇺🇸

Bellevue Hosp Ctr, New York, New York, United States

A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
36
Registration Number
NCT00000812
Locations
🇺🇸

University of Colorado Hospital CRS, Aurora, Colorado, United States

🇺🇸

University of Minnesota, ACTU, Minneapolis, Minnesota, United States

🇺🇸

Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy